Riskpilot← Back to searchSign inGet full accessSPANNAVEGEN APOTEK AS
ASActiveOrg 922699321Retail sale of pharmaceutical products · NACE 4773Est. 20199 employees
Revenue 2023
NOK 1,3M
-96% vs 2022
EBITDA margin
-10.8%
-112% vs 2022
Equity ratio
18.4%
Financial strength
Net profit 2023
NOK -121K
-114% vs 2022
| Revenue | NOK 1,3M | -96% |
| EBITDA | NOK -144K | -112% |
| Net profit | NOK -121K | -114% |
| Total assets | NOK 5,7M | +28% |
| Equity | NOK 1M | -10% |
| Employees | 9 | — |
Legal name
SPANNAVEGEN APOTEK AS
Org number
922699321
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
3. mai 2019
Share capital
NOK 9 961 000
Employees
9 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-01-31
Financial year
January – December
Signatory rights
Utgår
Company purpose
Drive apoteksvirksomhet, og alt hva dermed kan forbindes.
Address
Phone
+4752723200
Email
apotek1.spannavegen@apotek1.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 1 504 | 12 652 | 27 903 | 30 092 | 1 336 |
| Staff expenses | −490 | −2 248 | −4 678 | −4 552 | −403 |
| EBITDA | −289 | 288 | 536 | 1 230 | −144 |
| Depreciation & amort. | −30 | −128 | −141 | −146 | −11 |
| EBIT | −320 | 160 | 395 | 1 084 | −155 |
| Net financials | 0 | −0 | −0 | 2 | −1 |
| Profit before tax | −319 | 160 | 394 | 1 086 | −155 |
| Tax | −0 | −0 | 51 | 239 | −34 |
| Net profit | −319 | 160 | 343 | 847 | −121 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 4 107 | 4 202 | 7 949 | 4 411 | 5 657 |
| Equity | −225 | 35 | 379 | 1 165 | 1 044 |
| Long-term debt | 1 500 | 2 200 | 2 251 | 75 | 41 |
| Short-term debt | 2 832 | 1 967 | 5 319 | 3 172 | 4 573 |
| Total debt | 4 332 | 4 167 | 7 570 | 3 246 | 4 613 |
EBITDA margin
-10.8%
This company
15.8%
Market median
-168% vs market
20192023
Equity ratio
18.4%
This company
38.2%
Market median
-52% vs market
20192023
Return on equity
-11.6%
This company
18.4%
Market median
-163% vs market
20192023
Net profit margin
-9.1%
This company
8.1%
Market median
-212% vs market
20192023
Asset turnover
0.24×
This company
1.12×
Market median
-79% vs market
20192023
Debt / equity
4.42×
This company
0.62×
Market median
-613% vs market
20192023
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-01-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-02-06 – 2019-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2023 | |
| Board of Directors | 2023 | |
| Former (2) | ||
| Chairman | 2019 – 2023 | |
| Board of Directors | 2019 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SPANNAVEGEN APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Børge Moholt | Chairman | 0 companies |
| Linn Karin Amiri Oksebåsen | Chairman | 0 companies |
| Fabian Chia Amiri | Board of Directors | 0 companies |
| Øystein Askim | Board of Directors | 0 companies |